Access to 2-oxoazetidine-3-carboxylic acid derivatives via thermal microwave-assisted Wolff rearrangement of 3-diazotetramic acids in the presence of nucleophiles

• Ivan Lyutin,
• Vasilisa Krivovicheva,
• Grigory Kantin and
• Dmitry Dar’in

Beilstein J. Org. Chem. 2024, 20, 1894–1899, doi:10.3762/bjoc.20.164

• (SLC6A19) [10]. Hence, developing new synthetic methods to create structurally diverse 2-oxoazetidine-3-carboxylic acid derivatives is a highly valuable endeavour that could have a positive impact on future drug discovery. Most synthetic approaches to amides and esters of 2-oxoazetidine-3-carboxylic acids

2-Heteroarylethylamines in medicinal chemistry: a review of 2-phenethylamine satellite chemical space

• Carlos Nieto,
• Alejandro Manchado,
• Ángel García-González,
• David Díez and
• Narciso M. Garrido

Beilstein J. Org. Chem. 2024, 20, 1880–1893, doi:10.3762/bjoc.20.163

• area of chemical space of biological importance) in medicinal chemistry is the 2-phenethyl moiety, a key component of diverse drug-like entities. Although the core 2-phenethylamine structure has been recognized by the drug discovery community, little attention has been given to the various ring-based

• examples, which will be a valuable repository of phenyl, heteroaryl, and other replacement units of high value to the drug discovery community. Keywords: bioisosteres; 2-heteroarylethylamines; medicinal chemistry; 2-phenethylamine; scaffold hopping; Introduction One of the major hit-2-lead exploration

• structural hopping strategy, as five- or six-membered heterocyclic aromatic rings are widespread entities in drug discovery [4]. In this sense, any bioactive molecule enclosing a benzene ring in its initial optimization stages could undergo a heteroaromatic replacement. 2-Phenethylamines are notable

The Groebke–Blackburn–Bienaymé reaction in its maturity: innovation and improvements since its 21st birthday (2019–2023)

• Cristina Martini,
• Muhammad Idham Darussalam Mardjan and
• Andrea Basso

Beilstein J. Org. Chem. 2024, 20, 1839–1879, doi:10.3762/bjoc.20.162

• no loss of activity after 30 days. On the other hand, reusability seemed problematic, as significant decrement in yield was observed after the second cycle. Kinetic target-guided synthesis (KTGS) has emerged as a promising strategy in drug discovery [24]. It relies on a drug target serving as a

A facile three-component route to powerful 5-aryldeazaalloxazine photocatalysts

• Ivana Weisheitelová,
• Radek Cibulka,
• Marek Sikorski and
• Tetiana Pavlovska

Beilstein J. Org. Chem. 2024, 20, 1831–1838, doi:10.3762/bjoc.20.161

• 2, as demonstrated in our previous studies with 5-aryldeazaflavins 1 [14][15][16][17][18]. Multicomponent reactions (MCRs) remain a powerful strategy in synthetic organic chemistry due to their widespread applications in drug discovery. By offering significant advantages over conventional, linear

Oxidative fluorination with Selectfluor: A convenient procedure for preparing hypervalent iodine(V) fluorides

• Samuel M. G. Dearman,
• Xiang Li,
• Yang Li,
• Kuldip Singh and
• Alison M. Stuart

Beilstein J. Org. Chem. 2024, 20, 1785–1793, doi:10.3762/bjoc.20.157

• ; fluorobenziodoxoles; halogen bonding; hypervalent iodine; Selectfluor; Introduction An important strategy in the drug discovery process is the incorporation of fluorine into biologically active molecules because fluorine can improve bioactivity and pharmacokinetic properties [1]. Consequently, 22% of all small

Syntheses and medicinal chemistry of spiro heterocyclic steroids

• Laura L. Romero-Hernández,
• Ana Isabel Ahuja-Casarín,
• Penélope Merino-Montiel,
• Sara Montiel-Smith,
• José Luis Vega-Báez and
• Jesús Sandoval-Ramírez

Beilstein J. Org. Chem. 2024, 20, 1713–1745, doi:10.3762/bjoc.20.152

Chemo-enzymatic total synthesis: current approaches toward the integration of chemical and enzymatic transformations

• Ryo Tanifuji and
• Hiroki Oguri

Beilstein J. Org. Chem. 2024, 20, 1693–1712, doi:10.3762/bjoc.20.151

• synthesis; Introduction Naturally occurring organic compounds with potent biological activities continue to be compelling lead candidates for drug discovery, with advancements in their synthesis and supply techniques progressing rapidly. Of particular note is the progress made in the "chemo-enzymatic

Polymer degrading marine Microbulbifer bacteria: an un(der)utilized source of chemical and biocatalytic novelty

• Weimao Zhong and
• Vinayak Agarwal

Beilstein J. Org. Chem. 2024, 20, 1635–1651, doi:10.3762/bjoc.20.146

• ; hydrolases; marine natural products; Introduction Microbial natural products represent an important reservoir for drug discovery and along with their (semi)synthetic derivatives, constitute a major component of the contemporary pharmaceutical arsenal. Their thusly validated utility is juxtaposed against the

Generation of multimillion chemical space based on the parallel Groebke–Blackburn–Bienaymé reaction

• Evgen V. Govor,
• Vasyl Naumchyk,
• Ihor Nestorak,
• Dmytro S. Radchenko,
• Dmytro Dudenko,
• Yurii S. Moroz,
• Olexiy D. Kachkovsky and
• Oleksandr O. Grygorenko

Beilstein J. Org. Chem. 2024, 20, 1604–1613, doi:10.3762/bjoc.20.143

• showed biological activity according to the ChEMBL database. Keywords: fused rings; heterocycles; imidazoles; isonitrile; multicomponent reactions; Introduction Multicomponent reactions are widely recognized as a powerful source of biologically active compounds, in particular, for drug discovery

• can be considered as privileged chemotypes in drug discovery: their representatives include the sedative drug zolpidem, disease-modifying antirheumatic agent upadacitinib, anticancer drug capmatinib, or risdiplam, a medication for spinal muscular atrophy (SMA) treatment (Figure 1) [22][23]. Over the

• -component reactions are very effective for the generation of synthetically tractable ultra-large chemical space [30][31][32]. Such virtual but readily accessible (REAL) compound libraries demonstrated excellent performance in early drug discovery programs when combined with modern computational tools such

Supramolecular assemblies of amphiphilic donor–acceptor Stenhouse adducts as macroscopic soft scaffolds

• Ka-Lung Hung,
• Leong-Hung Cheung,
• Yikun Ren,
• Ming-Hin Chau,
• Yan-Yi Lam,
• Takashi Kajitani and
• Franco King-Chi Leung

Beilstein J. Org. Chem. 2024, 20, 1590–1603, doi:10.3762/bjoc.20.142

• Ka-Lung Hung Leong-Hung Cheung Yikun Ren Ming-Hin Chau Yan-Yi Lam Takashi Kajitani Franco King-Chi Leung The Hong Kong Polytechnic University Shenzhen Research Institute, Shenzhen 518057, China State Key Laboratory of Chemical Biology and Drug Discovery, Department of Applied Biology and Chemical

Benzylic C(sp³)–H fluorination

• Alexander P. Atkins,
• Alice C. Dean and
• Alastair J. J. Lennox

Beilstein J. Org. Chem. 2024, 20, 1527–1547, doi:10.3762/bjoc.20.137

• )–H functionalisation reactions in drug-discovery campaigns [17]. Although much is unknown about the precise details, several benzylic fluorides have been reported to be unstable, which is an effect that is apparently dependent on the substitution of the ring. While primary benzylic fluorides are

Primary amine-catalyzed enantioselective 1,4-Michael addition reaction of pyrazolin-5-ones to α,β-unsaturated ketones

• Pooja Goyal,
• Akhil K. Dubey,
• Raghunath Chowdhury and
• Amey Wadawale

Beilstein J. Org. Chem. 2024, 20, 1518–1526, doi:10.3762/bjoc.20.136

• (Scheme 2) were obtained in good to excellent yields (71–97%) and enantioselectivities (83.5–98% ee). Molecules containing two or more biologically relevant heterocycle motifs are receiving attention in drug discovery research [31][32][33]. The enantioselective synthesis of such hybrid molecules is

A comparison of structure, bonding and non-covalent interactions of aryl halide and diarylhalonium halogen-bond donors

• Nicole Javaly,
• Theresa M. McCormick and
• David R. Stuart

Beilstein J. Org. Chem. 2024, 20, 1428–1435, doi:10.3762/bjoc.20.125

• interaction in a wide range of applications that include crystal engineering, drug discovery and light-emitting materials [1][2][3][4]. Although, halogen bonding was first “observed” over 200 years ago [5][6] and the structural characteristics were elucidated in the latter half of the nineteenth century [7

Rhodium-catalyzed homo-coupling reaction of aryl Grignard reagents and its application for the synthesis of an integrin inhibitor

• Kazuyuki Sato,
• Satoki Teranishi,
• Atsushi Sakaue,
• Yukiko Karuo,
• Atsushi Tarui,
• Kentaro Kawai,
• Hiroyuki Takeda,
• Tatsuo Kinashi and
• Masaaki Omote

Beilstein J. Org. Chem. 2024, 20, 1341–1347, doi:10.3762/bjoc.20.118

• , Nishinomiya, Hyogo 662-0934, Japan Division of Proteo-Drug-Discovery Sciences, Ehime University Proteo-Science Center Bunkyo-cho, Matsuyama, Ehime, 790-8577, Japan, Department of Molecular Genetics, Institute of Biomedical Science, Kansai Medical University, 2-5-1 Shin-machi, Hirakata, Osaka, 573-1010, Japan

The Ugi4CR as effective tool to access promising anticancer isatin-based α-acetamide carboxamide oxindole hybrids

• Carolina S. Marques,
• Aday González-Bakker and
• José M. Padrón

Beilstein J. Org. Chem. 2024, 20, 1213–1220, doi:10.3762/bjoc.20.104

• , 38200, La Laguna, Spain 10.3762/bjoc.20.104 Abstract Considering early-stage drug discovery programs, the Ugi four-component reaction is a valuable, flexible, and pivotal tool, facilitating the creation of two new amide bonds in a one-pot fashion to effectively yield the desired α-aminoacylamides. Here

• chemists regarding process formation of new bonds and synthesis of new scaffolds. In drug discovery and development, medicinal chemists struggle everyday towards the creation of new synthetic methods, driven by the increasing complexity of the molecules and taking into consideration economic and social

• , aliphatic chain on the acid component and small aliphatic chain on the aldehyde component to increase the antiproliferative activity. Also, benzyl isocyanide was favored over the aliphatic one (Scheme 1A) [16]. Considering the value of amide groups in drug discovery [19], the feasibility of running the

Enhancing structural diversity of terpenoids by multisubstrate terpene synthases

• Min Li and
• Hui Tao

Beilstein J. Org. Chem. 2024, 20, 959–972, doi:10.3762/bjoc.20.86

• Min Li Hui Tao Department of Otolaryngology, Zhongnan Hospital of Wuhan University, School of Pharmaceutical Sciences, Wuhan University, Wuhan, Hubei 430071, China Key Laboratory of Combinatorial Biosynthesis and Drug Discovery, Ministry of Education, Wuhan University, Wuhan, Hubei 430071, China

Innovative synthesis of drug-like molecules using tetrazole as core building blocks

• Jingyao Li,
• Ajay L. Chandgude,
• Qiang Zheng and
• Alexander Dömling

Beilstein J. Org. Chem. 2024, 20, 950–958, doi:10.3762/bjoc.20.85

• showcase the versatility of these new tetrazole building blocks by integrating the tetrazole moiety into various multicomponent reactions (MCRs), which are already significantly employed in drug discovery. This technique represents a unique and complementary method to existing tetrazole synthesis processes

• . The well described, excellent functional group compatibility and versatility of MCRs along with their promising impact on medicinal chemistry and drug discovery for the library generation prompted us to further use the tetrazole building blocks in MCRs [31][32]. Building on our previous interest in

• developed building block approach, we decided to incorporate an oxo-tetrazole into an Ugi four-component reaction, the most studied and versatile MCR in organic synthesis and drug discovery [31][32]. Despite tremendous exploration, finding novel substrates or bioisosteres as a starting material in the Ugi

Three-component N-alkenylation of azoles with alkynes and iodine(III) electrophile: synthesis of multisubstituted N-vinylazoles

• Jun Kikuchi,
• Roi Nakajima and
• Naohiko Yoshikai

Beilstein J. Org. Chem. 2024, 20, 891–897, doi:10.3762/bjoc.20.79

• work was supported by JSPS KAKENHI (Grant No. 20K23375 (N.Y.) and 19K15552 (J.K.)), The Uehara Memorial Foundation (N.Y.), Research Support Project for Life Science and Drug Discovery (Basis for Supporting Innovative Drug Discovery and Life Science Research (BINDS)) from AMED (Grant No. JP23ama121040

(Bio)isosteres of ortho- and meta-substituted benzenes

• H. Erik Diepers and
• Johannes C. L. Walker

Beilstein J. Org. Chem. 2024, 20, 859–890, doi:10.3762/bjoc.20.78

• well as the impact they have on the physiochemical and biological properties of pharmaceuticals and agrochemicals. Keywords: bioisosteres; drug discovery; meta-benzene; ortho-benzene; Introduction The logical and iterative modification of the structure of a drug candidate is a critical part of the

• early drug discovery process. In many cases, the primary aim is the enhancement of biological activity, but in others, modulation of other critical properties such as aqueous solubility, metabolic stability, polarity, or lipophilicity is the target. In the latter cases, there is often a desire to retain

• straightforward synthesis of a wide-range of disubstituted BCPs from [1.1.1]propellane allows them to be easily integrated into drug discovery programmes. The case of Darapladib is one well-known example of a productive para-benzene-to-BCP bioisosteric switch [24]. By comparison, the number of bioisosteres of

Methodology for awakening the potential secondary metabolic capacity in actinomycetes

• Shun Saito and
• Midori A. Arai

Beilstein J. Org. Chem. 2024, 20, 753–766, doi:10.3762/bjoc.20.69

• drug discovery. However, it is becoming difficult to obtain novel compounds because of repeated isolation around the world. Therefore, a new strategy for discovering novel secondary metabolites is needed. Many researchers believe that actinomycetes have as yet unanalyzed secondary metabolic activities

• discovery studies, has been losing momentum. In drug discovery studies in the field of chemical biology, it may be important to investigate the compounds obtained by silent gene activation. It is expected that compounds useful in a variety of fields will be discovered by making full use of such silent gene

• , respectively. Analyses of the functionality of such metabolites may also lead to the elucidation of new life phenomena. However, in recent years, it has not only become increasingly difficult to obtain novel secondary metabolites from natural products, but applied research using natural products, such as drug

Genome mining of labdane-related diterpenoids: Discovery of the two-enzyme pathway leading to (−)-sandaracopimaradiene in the fungus Arthrinium sacchari

• Fumito Sato,
• Terutaka Sonohara,
• Shunta Fujiki,
• Akihiro Sugawara,
• Yohei Morishita,
• Taro Ozaki and
• Teigo Asai

Beilstein J. Org. Chem. 2024, 20, 714–720, doi:10.3762/bjoc.20.65

• of Tokyo) for providing the genome editing system of A. oryzae. Funding This work was supported by JSPS KAKENHI (22H02775 [T.A.], 23H04538 [T.O.], 22K19095 [T.O.]); AMED-CREST (23gm1610007 [T.A.]); Platform Project for Supporting Drug Discovery and Life Science Research (Basis for Supporting

• Innovative Drug Discovery and Life Science Research [BINDS]) from AMED [JP23ama121038 (T.A.) and JP23ama121040 (T.O.)].

New variochelins from soil-isolated Variovorax sp. H002

• Jabal Rahmat Haedar,
• Aya Yoshimura and
• Toshiyuki Wakimoto

Beilstein J. Org. Chem. 2024, 20, 692–700, doi:10.3762/bjoc.20.63

• ), Pharma Science Open Unit (PSOU), funded by MEXT under “Support Program for Implementation of New Equipment Sharing System”, Global Station for Biosurfaces and Drug Discovery, a project of Global Institution for Collaborative Research and Education in Hokkaido University, the Japan Agency for Medical

Palladium-catalyzed three-component radical-polar crossover carboamination of 1,3-dienes or allenes with diazo esters and amines

• Geng-Xin Liu,
• Xiao-Ting Jie,
• Ge-Jun Niu,
• Li-Sheng Yang,
• Xing-Lin Li,
• Jian Luo and
• Wen-Hao Hu

Beilstein J. Org. Chem. 2024, 20, 661–671, doi:10.3762/bjoc.20.59

• Geng-Xin Liu Xiao-Ting Jie Ge-Jun Niu Li-Sheng Yang Xing-Lin Li Jian Luo Wen-Hao Hu Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, Guangdong 510006, China 10.3762/bjoc.20.59 Abstract Herein, we report a visible

Chemical and biosynthetic potential of Penicillium shentong XL-F41

• Ran Zou,
• Xin Li,
• Xiaochen Chen,
• Yue-Wei Guo and
• Baofu Xu

Beilstein J. Org. Chem. 2024, 20, 597–606, doi:10.3762/bjoc.20.52

• Ran Zou Xin Li Xiaochen Chen Yue-Wei Guo Baofu Xu Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, Shandong 264117, China School of Life Sciences, Ludong University, Yantai 264025, China State Key Laboratory of Drug Research, Shanghai

• database confirmed its identification as Penicillium sp. This strain is preserved at the Shandong Laboratory of Yantai Drug Discovery. Fermentation in shaking flasks For large-scale fermentations, fresh mycelia of Penicillium shentong XL-F41 were first cultivated in liquid potato dextrose broth at 28 °C

• clusters of the Penicillium shentong XL-F41. Supporting Information Supporting Information File 38: NMR and mass spectra of isolated compounds. Acknowledgements We thank Congcong Guo and the Pharmaceutical Analysis and Quality Research Platform of Bohai Rim Advanced Research Institute for Drug Discovery

A new analog of dihydroxybenzoic acid from Saccharopolyspora sp. KR21-0001

• Rattiya Janthanom,
• Yuta Kikuchi,
• Hiroki Kanto,
• Tomoyasu Hirose,
• Arisu Tahara,
• Takahiro Ishii,
• Arinthip Thamchaipenet and
• Yuki Inahashi

Beilstein J. Org. Chem. 2024, 20, 497–503, doi:10.3762/bjoc.20.44

• Actinomycetes are well-known as the main producers of bioactive compounds such as antibiotics, anticancers, and immunosuppressants. Screening of natural products from actinomycetes has been an essential part of several drug discovery programs. Finding such novel biologically active metabolites is immensely

• the Ministry of Education, Culture, Sports, Science, and Technology of Japan under grant no. 19H05685, Okinawan Create Leading Projects in Growing Fields 2017-2019 and 2020-2021, OKINAWA Prefectural Government, and the Platform Project for Supporting Drug Discovery and Life Science Research (Basis for

• Supporting Innovative Drug Discovery and Life Science Research; BINDS) from the Japan Agency for Medical Research & Development (AMED) under grant no. JP19am0101096 (Phase I) and JP22ama121035 (Phase II).